Alpha Teknova (TKNO) Q2 2026 earnings summary

Executive summary

• Achieved record Q2 2026 revenue of $12.2 million, up 18–18.5% year-over-year, with growth across nearly all end markets and both Lab Essentials and Clinical Solutions segments contributing.

• Launched Build-Tek, an AI-powered custom order configurator, to accelerate custom product sales and improve customer experience.

• Raised full-year 2026 revenue guidance to $45–$47 million, implying 14% growth at the midpoint, and improved Free Cash Outflow expectations to less than $8 million.

• Gross margin improved to 40.1% from 38.7% in Q2 2025, reflecting operational efficiencies.

• Net loss for Q2 2026 was $3.2 million or -$0.06 per share, improved from $3.6 million or -$0.07 per share.

Financial highlights

• Q2 2026 total revenue: $12.2 million, up 18% from $10.3 million in Q2 2025.

• Lab Essentials revenue: $9.2 million (up 17.9–18%); Clinical Solutions revenue: $2.4 million (up 17.9–18%).

• Gross profit: $4.9 million, up from $4.0 million; gross margin: 40.1% (up from 38.7%).

• Adjusted EBITDA: -$0.7 million, improved from -$0.8 million year-over-year.

• Free cash outflow: $0.6 million, down from $2.3 million year-over-year.

Outlook and guidance

• 2026 revenue guidance raised to $45–$47 million (from $42–$44 million), with 14% growth at midpoint.

• Free cash outflow for 2026 anticipated to be less than $8 million.

• Adjusted EBITDA positive expected at $52–$57 million annualized revenue, likely before end of 2027.

• Management expects expenses to increase at a slower rate as investments in personnel, infrastructure, and marketing continue.

• 2027 revenue outlook remains in the low $50 million range; 20% growth possible if tailwinds materialize.